CONSISTENT EFFECT OF EMPAGLIFLOZIN ON COMPOSITE OUTCOMES RELATED TO HEART FAILURE: RESULTS FROM EMPA-REG OUTCOME

Background: In the EMPA-REG OUTCOME trial, empagliflozin (EMPA) given in addition to standard of care significantly reduced the risk of cardiovascular (CV) death by 38%, hospitalization for heart failure (HHF) by 35%, and the composite of HHF or CV death by 34% vs placebo in patients with type 2